In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A

Blood

Volumn 87, Issue 9, 1996, Pages 4001-4009

  Blazar, Bruce R ^a   Taylor, Patricia A ^b   Panoskaltsis Mortari, Angela ^b   Sehgal, Suren ^b   Vallera, Daniel A ^b  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE; CYCLOSPORIN A; CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; RAPAMYCIN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG INFILTRATE; LYMPHOCYTE DEPLETION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SKIN DEFECT; SYNDROME; T LYMPHOCYTE; THYMECTOMY;

EID: 0029872662     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.9.4001.bloodjournal8794001     Document Type: Article

References (51)

1. Korngold R, Sprent J: T-cell subsets and GVHD. Transplantation 44:335, 1977
2. Vallera DA, Blazar BR: T-cell depletion for graft-versus-host disease (GVHD) prophylaxis: A perspective on engraftment in mice and humans. Transplantation 47:751, 1989
3. Storb R, Deeg HJ, Whitehead J, Appelbaum FR, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute GVHD after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
4. Ramsay NKC, Kersey JH, Robison LL, McGlave P, Woods WG, Krivit W, Kim TM, Goldman AI, Nesbit ME: A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 306:392, 1982
5. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, Kersey JH, Filipovich A: Risk factors for acute GVHD in histocompatible donor bone marrow transplantation. Transplantation 51:1197, 1991
6. Verzina C, Kudelski A, Sehgal SN: Rapamycin (AY-22,989), a new antifungal antibiotic: I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28:721, 1975
7. Sehgal SN, Baker H, Verzina C: Rapamycin (AY-22,989), a new antifungal antibiotic: II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 28:727, 1975
8. Blazar BR, Taylor PA, Snover DC, Sehgal SN, Vallera DA: Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol 151:5726, 1993
9. Blazar BR, Taylor PA, Sehgal SN, Vallera DA: Rapamycin prolongs survival of murine recipients of fully allogeneic donor grafts when administered during the graft-versus-host disease process. Ann NY Acad Sci 685:73, 1993
10. Blazar BR, Taylor PA, Sehgal SN, Vallera DA: Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood 83:600, 1994
11. Glazier A, Tutschka PJ, Farmer ER, Santos GW: Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous reconstitution. J Exp Med 158:1, 1983
12. Glazier A, Tutschka PH, Farmer ER: Studies on the immunobiology of syngeneic and autologous graft-versus-host disease in cyclosporine treated rats. Trans Proc 15:3035, 1983
13. Hess AD, Horwitz L, Beschorner WE, Santos GW: Development of graft-versus-host disease-like syndrome in cyclosporin treated rats after syngeneic bone marrow transplantation: I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity including autoreactivity. J Exp Med 161:718, 1985
14. Sorokin R, Kimura H, Schroder K, Wilson DH, Wilson DB. Cyclosporine-induced autoimmunity: Conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats. J Exp Med 164:1615, 1986
15. Chow LH, Mosbach-Ozmen L, Ryffel B, Borel JF: Syngeneic graft-versus-host disease induced by cyclosporine - A reappraisal of the autoimmune-like syndrome. Transplantation 46.107S, 1988 (suppl 2)
16. Bryson JS, Jennings CD, Caywood BE, Kaplan AM: Induction of a syngeneic graft-versus-host disease-like syndrome in DBA/ 2 mice. Transplantation 48:1042, 1989
17. Bucy RP, Xu XY, Li J, Huang GQ: Cyclosporin A-induced autoimmune disease in mice. J Immunol 151:1039, 1993
18. Beschorner WE, Hess AD, Shinn CA, Santos GW: Transfer of cyclosporine-associated syngeneic graft-versus-host disease by thymocytes. Resemblance to chronic graft-versus-host disease. Transplantation 45:209, 1988
19. Martel RR, Klicis J, Galet S: Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 55:48, 1977
20. Chang JY, Sehgal SN, Bansbach CC: FK506 and rapamycin: Novel pharmacological probes of the immune response. Trends Pharmacol Sci 12:218, 1991
21. Metcalfe S, Milner J: Evidence that FK506 and rapamycin block T-cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. Transplantation 51:1318, 1990
22. Metcalfe SM, Richards FM: Cyclosporine, FK506, and rapamycin. Transplantation 49:798, 1990
23. Crabtree GR: Contingent genetic regulatory events in T lymphocyte activation. Science 243:355, 1989
24. June CH, Ledbetter JA, Linsley PS, Thompson CB: Role of the CD28 receptor in T-cell activation. Immunol Today 11:211, 1990
25. Michnick SW, Rosen MK, Wandless TJ, Karplus M, Schreiber SL: Solution structure of FKBP, a roamase enzyme and receptor for FK506 and rapamycin. Science 252:836, 1991
26. Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J: Atomic structure of FKBP-FK506, an immunophilin immunosuppressant complex. Science 252:839, 1991
27. Dumont F, Melino J, Staruch MJ, Koprak SL, Fischer PA, Sigal NH: Distinct mechanisms of suppression of murine T-cell activation by the related macrolides FK506 and rapamycin. J Immunol 144:251, 1990
28. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, Schreiber SL: Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 87:9231, 1990
29. Bierer BE, Somers PK, Wandless TJ, Burakoff SJ, Schreiber SL: Probing immunosuppressant action with a nonnatural immunophilin ligand. Science 250:556, 1990
30. Beschorner WE, Olson JL, Hess D, Di Gennaro KA, Santos GW: Cyclosporine-induced cell-mediated injury of the thymic medullary epithelium. Transplantation 45:797, 1988
31. Shinozawa T, Beschorner WE, Hess AD: The thymus and prolonged administration of cyclosporine. Irreversible immunopathologic changes associated with autologous pseudo-graft-versus-host disease. Transplantation 50:106, 1990
32. Fischer AC, Ruvolo PP, Burt R, Horwitz LR, Bright EC, Hess JM, Beschorner WE, Hess AD: Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. J Immunol 154:3713, 1995
33. Jenkins MK, Schwartz RH, Pardoll DM: Effects of cyclosporine A on T-cell development and clonal deletion. Science 241:1655, 1988
34. Gao EK, Lo D, Cheney R, Kanagawa O, Sprent J: Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 336 176, 1988
35. Bryson JS, Caywood BE, Kaplan AM: Relationship of cyclosponne A-mediated inhibition of clonal deletion and development of syngeneic graft-versus-host disease. J Immunol 147:391, 1991
36. Hess AD, Fischer AC, Horwitz L, Bright EC, Laulis M: Characterization of the peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. J Immunol 153:400, 1994
37. Vallera DA, Carroll SF, Snover D, Carlson GJ, Blazar BR: Toxicity and efficacy of anti-T-cell ricin toxin A chain (RTA) immunotoxins in a murine model of ongoing GVHD across the major histocompatibility barrier. Blood 77:182, 1990
38. Biazar BR, Taylor PA, Fitzsimmons WE, Vallera DA: FK506 inhibits murine graft-versus-host disease and bone marrow graft rejection in murine recipients of major histocompatibility complex (MHC) disparate donor grafts by interfering with mature peripheral T-cell expansion post-transplantation. J Immunol 153:1836, 1994
39. Mowat AM, Felstein MV, Baca ME: Experimental studies of immunologically mediated enteropathy. III. Severe and progressive enteropathy during a graft-versus-host reaction in athymic mice. Immunology 61:185. 1987
40. Vallera DA, Taylor PA, Widmer MB, Blazar BR: IL-1α mediated promotion of long-term alloengraftment and short-term neutrophil expansion does not require the presence of either donor or host cells. (Submitted)
41. Fischer AC, Beschorner WE, Hess AD: Requirements for the induction and adoptive transfer of cyclosporine-induced syngeneic graft-versus-host disease. J Exp Med 169:1031, 1989
42. Hess AD, Fischer AC, Beschorner WE: Effector mechanisms in cyclosponne A-induced syngeneic graft-versus-host disease. Role of CD4+ and CD8+ T lymphocyte subsets. J Immunol 145:526, 1990
43. - surface phenotype and the α,β heterodimer of the T-cell antigen receptor. J Immunol 143:1118, 1989
44. - alpha/beta bone marrow T-cells with suppressor activity. J Immunol 148:373, 1992
45. + cells. J Immunol 45:3209, 1990
46. Blazar BR, Taylor PA, Gray GS, Vallera DA: The role of T cell subsets in regulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or minor histocompatibility (miH) only disparate donor inocula. Transplantation 58:1422, 1994
47. Blazar BR, Thiele DL, Vallera DA: Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: Elimination of graft-versus-host disease without detrimental effects on engraftment. Blood 75:798, 1990
48. Korngold R, Sprent J: Lethal GVHD across minor histocompatibility barriers: Nature of the effector cells and role of the H-2 complex. Immunol Rev 71:5, 1983
49. Korngold R, Sprent J: Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med 165:1552, 1987
50. Fiorillo MT, Toniatti C, Van Snick J, Ciliberto G: Expression of the murine interleukin 6 receptor in hepatoma cells: The intracytoplasmic domain is not required for interleukin 6 signal transduction. Eur J Immunol 22:799, 1992
51. Sykes M, Harty MW, Pearson DA: Strain dependence of interleukin-2-induced graft-versus-host disease protection: Evidence that interleukin-2 inhibits selected CD4 functions. J Immunother 15:11, 1994